News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Vivalis, GlaxoSmithKline Win OK For First Human Trial With EB66
November 24, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PARIS Nov 24 (Reuters) - French biotech Vivalis (VLS.PA) and its British partner GlaxoSmithKline (GSK.L) have won U.S. clearance to begin testing for the first time on humans flu vaccines that were produced using Vivalis's technology.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Europe
GlaxoSmithKline
MORE ON THIS TOPIC
Insights
Redefining Obesity Treatment Beyond GLP-1 Limits
February 19, 2026
·
1 min read
·
Jennifer Smith-Parker
Insights
Muscle Preservation, Tolerability and Alternative Administration Routes Define Obesity’s Drug Future
February 19, 2026
·
2 min read
·
Jennifer Smith-Parker
FDA
FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision
February 18, 2026
·
3 min read
·
Heather McKenzie
Podcast
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
February 18, 2026
·
1 min read
·
Heather McKenzie
